Adderall IR

Phase 2Small molecule

UUniversity of Wyoming

Adderall IR is one of 9 small molecule programs targeting Medication. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MedicationRecruiting

MedicationPhase 2

Recruiting

Competition

Competitive Landscape

12 competitors in Medication

#DrugCompanyPhaseTrials

Ozempic

Novo Nordisk

Approved

1 2

Advil

KKenvue Brands

Approved

2 3

Methylphenidate /kg

FFlorida International University

Phase 3

1 4

Vyvanse

Takeda

Preclinical

1 5

Adderall IR

UUniversity of Wyoming

Phase 2

1 6

Tianeptine

Pfizer

Preclinical

1 7

Biodentine

IIstanbul University

Preclinical

1 8

Antiretroviral Drugs

NNational Institute of Allergy and Infectious Diseases (NIAID)

Preclinical

1 9

Glycyrrhizin

MMansoura University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Medication1 trial

Acute Effects of Stimulant Medication in College Students With ADHD

Recruiting·UUniversity of Wyoming·Phase 2·NCT03935646·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adderall IR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adderall IR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adderall IR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Wyoming company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Wyoming

Adderall IR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Medication1 trial

References

Drug Info

Quick Facts

Related News